Indication

In combination with chemotherapy in:

  • the neoadjuvant treatment of adult patients with HER2-positive, locally advanced, inflammatory, or early stage breast cancer at high risk of recurrence
  • the adjuvant treatment of adult patients with HER2-positive early breast cancer at high risk of recurrence

In combination with docetaxel in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.

Medicine details

Medicine name:
pertuzumab/trastuzumab (Phesgo)
SMC ID:
SMC2364
Pharmaceutical company
Roche
BNF chapter
Malignant disease and immunosuppression
Submission type
Abbreviated
Publication due date:
12 July 2021